<DOC>
	<DOCNO>NCT00730613</DOCNO>
	<brief_summary>RATIONALE : Cellular adoptive immunotherapy may stimulate immune system different way stop cancer cell grow . PURPOSE : This clinical trial study side effect cellular adoptive immunotherapy use genetically modify T-lymphocytes see well work treat patient recurrent refractory high-grade malignant glioma .</brief_summary>
	<brief_title>Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes Treating Patients With Recurrent Refractory High-Grade Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess feasibility safety cellular immunotherapy utilize ex vivo expand autologous CD8-positive T-cell clone genetically modify express IL-13 zetakine chimeric immunoreceptor Hy/TK selection/suicide fusion protein patient recurrent refractory , high-grade malignant glioma . Secondary - To evaluate antitumor activity adoptively transfer clone patient . - To screen development anti-IL13 zetakine anti-HyTK immune response patient . - To evaluate efficacy ganciclovir administration ablate transfer clone vivo toxicity encounter . OUTLINE : - Leukapheresis therapy preparation : Patients undergo leukapheresis obtain peripheral blood mononuclear cell . T-cells isolated peripheral blood genetically modify , hygromycin-resistant clone , expand ex vivo , cryopreserved first clinical radiographic evidence recurrence progression . Patients document disease recurrence progression undergo re-biopsy re-resection tumor placement reservoir-access device ( Rickham shunt ) tumor resection cavity prior autologous T-cell clone infusion therapy . - Autologous T-cell clone infusion : Patients receive infusion autologous antigen-specific CD8+ cytotoxic T-lymphocyte clone 5-10 minute day 1 , 3 , 5 week 1 2 . Treatment repeat every 3 week total 2 course absence disease progression unacceptable toxicity . Patients achieve tumor regression residual disease MRI 4 course study therapy may receive 2 additional course absence disease progression , unacceptable toxicity , complete response . Patients undergo blood , cerebrospinal fluid , tissue sample collection periodically correlative study . Samples assess IL13Rα2 expression level , susceptibility redirect T-cell effector mechanism , tumor T-cell activation marker . After completion study treatment , patient follow monthly 3 month , every 3 month two year , annually least 15 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma original diagnosis Grade III IV disease Refractory recurrent disease Unifocal site original disease cerebral cortex No clinical evidence progressive encephalopathy Has undergone recent reresection recurrent progressive disease No communication tumor resection cavity ventricle deep cerebrospinal fluid pathway document postoperative MRI scan PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Life expectancy &gt; 3 month WBC ≥ 2,000/dL ANC &gt; 1,000/dL Platelet count ≥ 100,000/dL ( unsupported transfusion growth factor ) Creatinine &lt; 1.6 mg/dL Bilirubin &lt; 1.5 SGOT SGPT &lt; 2 time upper limit normal Not pregnant Negative pregnancy test Fertile patient must use effective contraception Able understand protocol basic element and/or risks/benefits participate pilot study No requirement supplemental oxygen keep saturation &gt; 95 % expect resolve within 2 week No uncontrolled cardiac arrhythmia No hypotension require pressor support No renal dialysis dependency No refractory seizure disorder No concurrent nonmalignant illness poorly control treatment severity investigator deem unwise enter patient protocol No severe infection patient treat No history ganciclovir and/or Prohance contrast allergy intolerance No HIV positivity within past 3 month PRIOR CONCURRENT THERAPY : See Disease Characteristics Must recover major surgery At least 4 week since primary therapy steroid dependence At least 2 week since prior adjuvant cytotoxic chemotherapy recover No concurrent systemic corticosteroid , except use manage Tcell therapy toxicity No concurrent immunotherapy ( i.e. , interferon , vaccine , cellular product ) No concurrent pentoxifylline No concurrent investigative agent No concurrent ganciclovir ganciclovir derivative No concurrent acyclovir nonlife threaten herpes virus infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymal giant cell astrocytoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult ependymoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
</DOC>